Patents Assigned to GLENMARK
  • Humanized antibodies specific for von Willebrand factor
    Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS
    Publication number: 20120157411
    Abstract: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: December 15, 2011
    Publication date: June 21, 2012
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Bipin Parsottam Kansagra, Venkata Ramana Yemireddy, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Girish Gudi
  • NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION
    Publication number: 20120142748
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.
    Type: Application
    Filed: January 14, 2011
    Publication date: June 7, 2012
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan MUTHUPPALANIAPPAN, Gopalan BALASUBRAMANIAN, Srinivas GULLAPALLI, Neelima Khairatkar JOSHI, Shridhar Narayanan
  • Tricyclic Compounds As mPGES-1 Inhibitors
    Publication number: 20120108583
    Abstract: The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 3, 2012
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Lakshminarayana Narayana, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
    Patent number: 8129401
    Abstract: The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 6, 2012
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant Atmaram Gharat, Balasubramanian Gopalan, Neelima Khairatkar Joshi
  • PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE
    Publication number: 20120045648
    Abstract: A solid crystalline form of 1-(2-[4-(6-methoxy-3,4-dihydronaphthalene-1-y) phenoxy]ethyl)pyrrolidine, and a preparing process thereof are provided. The aforesaid compound is a key intermediate in the synthesis of lasofoxifene. A process for preparing lasofoxifene, a process for purifying lasofoxifene tartrate, and a crystalline form of lasofoxifene tartrate are also provided.
    Type: Application
    Filed: April 27, 2010
    Publication date: February 23, 2012
    Applicant: GLENMARK GENERRICS LTD
    Inventors: Mubeen Ahmed Khan, Nikhil Rasiklal Trivedi, Nagan Nirmalan Kandasamy, Dayaghan Gangadhar Patil, Vipin Kumar Pandey
  • Fused pyrimidineone compounds as TRPV3 modulators
    Patent number: 8119647
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: February 21, 2012
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Prasada Rao V. S. Lingam, Sachin Sundarlal Chaudhari, Abraham Thomas, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS
    Publication number: 20120041011
    Abstract: The present invention relates to substituted benzofused derivatives, which can he used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.
    Type: Application
    Filed: July 1, 2011
    Publication date: February 16, 2012
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant Atmaram GHARAT, Uday Mukund JOSHI, Neelima KHAIRATKAR-JOSHI, Suresh Mahadev KADAM
  • Processes for the Preparation of Indiplon and Intermediates Thereof
    Publication number: 20120028045
    Abstract: The present invention relates to processes for the preparation of indiplon and its polymorphic mixtures.
    Type: Application
    Filed: March 18, 2010
    Publication date: February 2, 2012
    Applicant: Glenmark Generics LTD
    Inventors: Joseph Prabahar Koilpillai, Sanjay Anantha Kale, Laxmikant Madhukar Kelkar, Sunil Sudhakar Zope, Mubeen Ahmed Khan
  • PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE
    Publication number: 20120022047
    Abstract: The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same.
    Type: Application
    Filed: March 30, 2010
    Publication date: January 26, 2012
    Applicant: GLENMARK GENERICS LTD
    Inventors: Joseph Prabahar Koilpillai, Pravin Bhalchandra Kulkarni, Sachin Bapurao Sawant, Nagesh Devidasrao Limbekar
  • Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
    Patent number: 8097729
    Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: January 17, 2012
    Assignee: Glenmark Generics Ltd.
    Inventors: Mangesh Shivram Sawant, Maloyesh Mathuresh Biswas, Mubeen Ahmed Khan, Sukumar Sinha, Nitin Sharad Chandra Pradhan
  • ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS
    Publication number: 20120010223
    Abstract: The present invention is related to novel isothiazolo[3,4-d]pyrimidinedione and isothiazolo[5,4-d]pyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: March 22, 2010
    Publication date: January 12, 2012
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay
  • PROCESS FOR THE PREPARATION OF VORICONAZOLE
    Publication number: 20110312977
    Abstract: The present invention provides a process for preparation of racemic voriconazole in a single reaction vessel. The present invention also provides a process for preparation of voriconazole using racemic voriconazole and the process of making it therewith.
    Type: Application
    Filed: February 4, 2010
    Publication date: December 22, 2011
    Applicant: GLENMARK GENERICS LIMITED
    Inventors: Francis Paul D'Souza, Premkumar Ramraj Yadav, Shankar Sanganabhatla, Mubeen Ahmed Khan
  • Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof
    Publication number: 20110281928
    Abstract: The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.
    Type: Application
    Filed: January 24, 2010
    Publication date: November 17, 2011
    Applicant: GLENMARK GENERICS LTD
    Inventors: Mubeen Ahmed Khan, Roop Singh Yadav, Nikhil Rasiklal Trivedi, Sachin Mahedo Lad
  • FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST
    Publication number: 20110257193
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: December 23, 2009
    Publication date: October 20, 2011
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: V. S. Prasadarao Lingam, Abraham Thomas, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS
    Publication number: 20110237659
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: November 6, 2009
    Publication date: September 29, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Sachin Sundarlal Chaudhari, Abraham Thomas, Ashok Bhausaheb Kadam, Sachin Vasantrao Dhone, Bharat Gangadhar Adik, Neelima Khairatkar-joshi, Vidya Ganapati Kattige
  • PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM
    Publication number: 20110207779
    Abstract: The present invention relates to a process for the preparation of esomeprazole magnesium containing R-isomer greater than about 0.1% by wt. In particular, the present invention relates to a process for the preparation of esomeprazole magnesium dihydrate containing R-isomer greater than about 0.1% by wt.
    Type: Application
    Filed: April 28, 2010
    Publication date: August 25, 2011
    Applicant: GLENMARK GENERICS LTD
    Inventors: Koilpillai Joseph Prabahar, Veerabhadra Swamy Hiremath, Milind Moreshwar Gharpure, Nagan Nirmalan Kandaswamy, Avekumar Digambar Dabe, Kamal Mehta, Pankajkumar Shinde
  • NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20110190303
    Abstract: The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
    Type: Application
    Filed: April 15, 2011
    Publication date: August 4, 2011
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant Atmaram Gharat, Balasubramanian Gopalan, Neelima Khairatkar Joshi
  • TISSUE SELECTIVE STEAROYL-COA DESATURASE 1 INHIBITORS AND CELL BASED SCREENING ASSAY FOR THEIR IDENTIFICATION
    Publication number: 20110184027
    Abstract: The present invention provides a method of treating a disorder treatable by administering a therapeutically effective amount of a tissue selective Stearoyl-CoA Desaturase 1 (SCD-1) modulator to a subject. In one embodiment, the present invention provides a method of treating a disorder treatable by administering a pharmaceutically effective amount of a tissue selective SCD-1 inhibitor to a subject. The invention also provides whole cell based screening assays to identify agents that selectively modulate the activity of SCD-1. This invention further provides whole cell based screening assays to identify agents that differentially inhibit SCD in different body tissues.
    Type: Application
    Filed: September 25, 2008
    Publication date: July 28, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima Khairatkar-Joshi, Daisy Shah, Laxmikant Atmaram Gharat, Lakshminarayana Narayana
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS
    Publication number: 20110160213
    Abstract: The present invention relates to the pharmaceutical compositions, more particularly to the pharmaceutical compositions comprising novel phosphodiesterase type 4 (PDE4) inhibitors, and their use in treating allergic and inflammatory disorders.
    Type: Application
    Filed: January 31, 2008
    Publication date: June 30, 2011
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Ulhas Dhuppad, Ganga Srinivas Arra